Wierdl_2016_Br.J.Pharmacol_173_2811

Reference

Title : Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer - Wierdl_2016_Br.J.Pharmacol_173_2811
Author(s) : Wierdl M , Tsurkan L , Hatfield MJ , Potter PM
Ref : British Journal of Pharmacology , 173 :2811 , 2016
Abstract :

Carboxylesterases (CEs) are ubiquitous enzymes responsible for the detoxification of ester-containing xenobiotics. This hydrolysis reaction results in the formation of the corresponding carboxylic acid and alcohol. Due to their highly plastic active site, CEs can hydrolyze structurally very distinct and complex molecules. Because ester groups significantly increase the water solubility of compounds, they are frequently used in the pharmaceutical industry to make relatively insoluble compounds more bioavailable. By default, this results in CEs playing a major role in the distribution and metabolism of these esterified drugs. However, this can be exploited to selectively improve compound hydrolysis, and using specific in vivo targeting techniques can be employed to generate enhanced drug activity. Here, we seek to detail the human CEs involved in esterified molecule hydrolysis, compare and contrast these with CEs present in small mammals and describe novel methods to improve drug therapy by specific delivery of CEs to cells in vivo. Finally, we will discuss the development of such approaches for their potential application towards malignant disease.

PubMedSearch : Wierdl_2016_Br.J.Pharmacol_173_2811
PubMedID: 27423046

Related information

Citations formats

Wierdl M, Tsurkan L, Hatfield MJ, Potter PM (2016)
Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer
British Journal of Pharmacology 173 :2811

Wierdl M, Tsurkan L, Hatfield MJ, Potter PM (2016)
British Journal of Pharmacology 173 :2811